Detalhe da pesquisa
1.
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
Ann Neurol
; 78(2): 248-57, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26061140
2.
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease.
Alzheimers Dement
; 10(5): 571-81, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24411134
3.
Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer.
Hum Gene Ther
; 27(7): 522-7, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26711317
4.
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's disease.
Neurobiol Aging
; 34(1): 35-61, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22926166
5.
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients.
Neurology
; 80(18): 1698-701, 2013 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-23576625